Status:
NOT_YET_RECRUITING
Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC
Lead Sponsor:
Shanghai Chest Hospital
Conditions:
ALK-Positive NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective, multicenter, non-interventional, single-arm, real-world study planned to be conducted in China, aimed at exploring the resistance mechanisms of first-line lorlatinib treatment i...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Age: Patients aged 18 years or older;
- Histologically or cytologically confirmed locally advanced or metastatic NSCLC
- Documened ALK resrrangemen by approved test (eg.. FisH,IHC. .r NGS).
- first-line loelaninab treatment fom Apr2023-Apr-2027.
- Evidenoe of popression to first-line lorlztinib within 2 weekes.
- Exclusion Criteria
- Previous treatment with other ALK-TKIs: Patients who have previously received any ALK TKI other than lorlatinib;
- Concomitant medications: Patients who have received any systemic anti-tumor treatment other than lorlatinib before enrollment.
Exclusion
Key Trial Info
Start Date :
April 20 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06904547
Start Date
April 20 2025
End Date
December 31 2030
Last Update
April 11 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.